{
  "id": "nsclc-pd1-main",
  "display_name": "NSCLC Immuno-Oncology (Main)",
  "cohort": "NSCLC, 1st Line (2024-2025)",
  "insight_type": "Utilization Gap",
  "summary": "Dr. Jones prescribes PD-1 to 37% of eligible NSCLC patients, 33% below NCCN guidance. Closing this gap could yield $112,300/year.",
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      { "name": "Dr. Jones", "value": 37, "gap": -33, "highlight": true },
      { "name": "Dr. Chen", "value": 58, "gap": -12, "highlight": false },
      { "name": "Dr. Garcia", "value": 65, "gap": -5, "highlight": false },
      { "name": "Dr. Wilson", "value": 82, "gap": 12, "highlight": false }
    ],
    "benchmark": 70,
    "nccn_target": 70
  },
  "financial_impact": {
    "annual_opportunity": "$112,300/year",
    "math": "$112,300/year = 33 patients × $3,403 margin per patient"
  },
  "clinical_impact": {
    "description": "PD-1 inhibitors significantly improve survival outcomes in NSCLC patients with ≥1% PD-L1 expression.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+8.7 months",
        "description": "Median progression-free survival benefit"
      },
      {
        "type": "OS",
        "value": "+11.8 months",
        "description": "Median overall survival benefit"
      },
      {
        "type": "ORR",
        "value": "+26%",
        "description": "Improved objective response rate"
      },
      {
        "type": "QoL",
        "value": "+18%",
        "description": "Enhanced quality of life measures"
      },
      {
        "type": "Hosp",
        "value": "-22%",
        "description": "Reduced hospitalization rate"
      }
    ],
    "quantitative": "+11.8 months OS"
  },
  "peer_comparison": {
    "description": "Dr. Jones prescribes PD-1 to 37% of eligible patients, 31% below peer average. Closing this gap could yield $105,500/year.",
    "peer_benchmark": 68,
    "financial_impact": {
      "annual_opportunity": "$105,500/year",
      "math": "$105,500/year = 31 patients × $3,403 margin per patient"
    },
    "action_steps": [
      {
        "text": "Schedule peer-to-peer learning between Dr. Jones and Dr. Wilson",
        "icon": "users"
      },
      {
        "text": "Share top-performer best practices with Dr. Jones",
        "icon": "document"
      },
      {
        "text": "Implement peer benchmark monitoring dashboard",
        "icon": "chart"
      },
      {
        "text": "Create provider-specific feedback loops",
        "icon": "clipboard"
      }
    ]
  },
  "weighted_score": 88,
  "action_steps": [
    {
      "text": "Flag NSCLC patients eligible for PD-1 but untreated",
      "icon": "flag"
    },
    {
      "text": "Start provider alignment discussion with Dr. Jones",
      "icon": "users"
    },
    {
      "text": "Share NCCN/PD-1 one-pager with practice team",
      "icon": "document"
    },
    {
      "text": "Set monitoring alert for 1L PD-1 adherence",
      "icon": "alert"
    }
  ],
  "suggestions": [],
  "drilldowns": [
    {
      "label": "View by Payer Type",
      "cohort": "NSCLC, 1L, by Payer Type",
      "jsonFile": "nsclc-pd1-by-payer.json",
      "drilldownLevel": 1
    }
  ]
} 